We are international
Donate
• health professionals TEXT SIZE   
back

Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses.
06.10.07
Click here to see video


 related articles